Friday, Aethlon Medical Inc (NASDAQ:AEMD) released results from an in vitro binding study of its Hemopurifier in removing extracellular vesicles (EVs) from plasma. Extracellular vesicles contribute to inflammation.

The translational study provides preclinical evidence to support Aethlon's planned phase 1 safety, feasibility, and dose-finding clinical trials of the Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Merck & Co Inc's (NYSE:MRK) Keytruda or Bristol-Myers Squibb Co's (NYSE:BMY) Opdivo.

"The positive data from this in vitro binding study of the Hemopurifier is an important step forward for Aethlon, ahead of the potential start of our planned phase 1 oncology trials in Australia and India," stated James Frakes, Interim CEO and Chief Financial Officer of Aethlon Medical.

Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections and for use in organ transplantation.

In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses.

In preclinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluid by utilizing its proprietary lectin-based technology.

Price Action: AEMD shares are up 6.11% at $1.251 at last check Friday.

Photo via Shutterstock